タナカ　ジユンジ   TANAKA Junji   田中　淳司    所属   その他 その他    職種   非常勤嘱託
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
掲載誌名	正式名：Annals of hematology 略　 称：Ann Hematol ISSNコード：14320584/09395555
掲載区分	国外
巻・号・頁	99(10),pp.2393-2404
著者・共著者	Tachibana Takayoshi†, Najima Yuho, Akahoshi Yu, Hirabayashi Shigeki, Harada Kaito, Doki Noriko, Uchida Naoyuki, Fukuda Takahiro, Sawa Masashi, Ogata Masao, Takada Satoru, Tanaka Masatsugu, Matsuhashi Yoshiko, Tanaka Junji, Onizuka Makoto, Ichinohe Tatsuo, Atsuta Yoshiko, Kako Shinichi,
発行年月	2020/10
概要	The prognostic impacts of BCR-ABL1 fusion gene mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) remain unknown. Using data from a nationwide Japanese registry, we have evaluated the prognostic impact of BCR-ABL1 mutations prior to the first allogeneic hematopoietic cell transplantation (HCT). The cohort included 289 patients with a median of 48 years of age (range: 16-70). Point mutations were detected in 110 patients. Of these, 90 (82%) harbored T315I mutations, while 20 had other mutations. With a median follow-up period of 29 months (range: 1-125), outcomes after 2 years were worse with mutations than without (overall survival [OS]: 34% vs 68%, p < 0.001; relapse rate [RR]: 48% vs 18%, p < 0.001), particularly with the presence of the T315I mutation (OS: 29% vs 68%, p < 0.001; RR: 54% vs 18%, p < 0.001). OS was significantly worse in the T315I group even among the cohort with hematological (p < 0.001) or molecular complete remission (p = 0.025) as compared to the no mutation group. Multivariate analysis determined the prognostic impact of the T315I mutation (OS: hazard ratio [HR] = 2.19, 95% confidence interval [CI]: 1.5-3.3, p < 0.001; RR: HR = 2.51, 95% CI: 1.5-4.2, p < 0.001). This study is the first to report on the prognostic significance of BCR-ABL1 mutations in Ph + ALL.
DOI	10.1007/s00277-020-04212-1
PMID	32803312